Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting
BURLINGTON, Mass. and OXFORD, UK, October 19, 2021 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, III., from October 24 to 27, 2021. Details of selected oral and moderated poster presentations are listed below.
NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by "*" discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted.
Axumin (fluciclovine F18) presentations
- Category: Genitourinary Cancer
- Title: Detectability Rates and Impact on Management From High-Sensitivity Total-
- Body 18F-Fluciclovine PET/CT Scans in Patients With Prostate Cancer Biochemical Recurrence
- Presenter: Soheila Fayeghi Azghadi, MD, Department of Radiation Oncology,
- Comprehensive Cancer Center, University of California Davis, Sacramento, Calif.
- Session Title: Poster Q&A 05 - Session 05 - Genitourinary Cancer, Hematology Malignancies,
- and Sarcoma and Cutaneous Tumors
- Presentation Time: 1:30 PM CT
- Location: McCormick Place West, Outside Room W375
- Presentation No.: 2532
- Category: Genitourinary Cancer
- Title: Randomized Trial of Conventional vs Conventional plus Fluciclovine (18F)
- PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer:
- Volumetric and Patient-Reported Toxicity Analyses
- Presenter: Vishal Ramesh Dhere, MD, Winship Cancer Institute, Department of Radiation
- Oncology, Emory University, Atlanta, Ga. Session Title: Poster Q&A 05 - Session 05 - Genitourinary Cancer, Hematology Malignancies,
- and Sarcoma and Cutaneous Tumors Presentation Time: 1:30 PM CT
- Location: McCormick Place West, Outside Room W375
- Presentation No.: 2547
- Category: Central Nervous System
- Session Title: 18F-Fluciclovine PET/CTto Distinguish Radiation Necrosis From Tumor Progression in Brain Metastases Treated With Stereotactic Radiosurgery: Results of a Prospective Pilot Study*
- Presenter:Martin C. Tom, MD, Department of Radiation Oncology, Taussig Cancer
- Institute, Cleveland Clinic, Cleveland, Ohio
- Session Title: 51 Oral presentation
- Presentation Time 12:15 PM CT
- Location: McCormick Place West, Room W194 a/b
- Presentation No.:51